All News
Filter News
Found 320 articles
-
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
3/22/2023
AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).
-
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
3/14/2023
AbCellera (Nasdaq: ABCL) today announced two upcoming poster presentations on its T-cell engager platform at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19.
-
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
3/6/2023
Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent program and corporate developments.
-
Carterra Expands Best-in-Class Franchise With the Launch of the LSAXT High-Throughput SPR Biosensor at SLAS 2023
2/27/2023
Carterra Expands Best-in-Class Franchise With the Launch of the LSA XT High-Throughput SPR Biosensor at SLAS 2023.
-
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
2/23/2023
AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
-
AbCellera Reports Full Year 2022 Business Results
2/21/2023
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022.
-
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
2/1/2023
AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
-
Unispace appoints respected life sciences leader
1/30/2023
Sam Gill to drive growth in evolving sector across Australia and New Zealand
-
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
1/25/2023
Juvena Therapeutics , Inc. announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies.
-
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
1/24/2023
AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
-
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
1/19/2023
AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No. 10,087,408 (the ‘408 Patent).
-
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
-
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
1/5/2023
Rallybio Corporation provided an update on recent accomplishments and announced expected 2023 clinical milestones.
-
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
1/4/2023
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
-
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
-
AbCellera and AbbVie Partner to Advance New Antibody Therapies
12/15/2022
AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV).
-
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
12/1/2022
AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
-
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
11/10/2022
AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.
-
AbCellera Reports Q3 2022 Business Results
11/8/2022
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2022.
-
AbCellera to Present at Upcoming Investor Conferences in November 2022
11/4/2022
AbCellera announced that executives from the Company will present at the following investor conferences.